Navigation Links
Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
Date:1/26/2011

RICHMOND, Calif., Jan. 26, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its fourth quarter and full year 2010 financial results on Wednesday, February 2, 2011, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 39226355.  Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on February 2, 2011 to midnight ET on February 9, 2011. The conference call replay numbers for domestic and international callers are 800-642-1687 and 706-645-9291 respectively. The conference ID number for the replay is 39226355.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has a Phase 1 / 2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
2. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
3. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
4. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
5. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
6. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
8. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
9. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
10. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... , ... August 22, 2017 , ... ... pipeline built upon patented KBioBox technology, the extended GUIDE-Seq ananlysis. KBioBox has adapted ... computation pipeline to be provide scientists with easy to understand reports, extended indel ...
(Date:8/21/2017)... ... August 21, 2017 , ... Finalists have recently been ... centers that have implemented innovative products, services, and technology over the past year. ... financial impact/value, and market need. The applicants with the top three scores in ...
(Date:8/21/2017)... Linda, Ca (PRWEB) , ... August 21, 2017 ... ... has arranged for two speakers for this two-part educational webinar, in which attendees ... complex subunit, and associated protein factor composition. Along with an overview of the ...
(Date:8/18/2017)... ... 18, 2017 , ... OAI, a leading Silicon Valley, CA-based ... announces the new Model 800E front and backside, semi-automatic mask aligner system. This ... OAI has already received and installed several orders for the Model ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
Breaking Biology News(10 mins):